BACKGROUND: To determine the effect of memantine on axonal loss and visual function during the course of optic neuritis (ON). METHODS:Sixty ON patients in a single-center, institutional setting were randomly assigned to the memantine or placebo groups. Patients with first attack of acute unilateral optic neuritis, with visual symptoms of 8 days' duration or less were enrolled in this trial. No patient had known multiple sclerosis, and none had taken immunomodulatory agent prior to or at the time of presentation. For all patients, the following characteristics were recorded and compared at initial presentation and 3 months afterward: visual acuity, retinal nerve fiber layer (RNFL) thickness, visual field parameters (mean deviation and pattern standard deviation), visual evoked potential, and contrast sensitivity. RESULTS: Fifty-four patients completed the 3-month follow up. There were no significant differences between the placebo and memantine groups for any of the characteristics at initial presentation. After 3 months, the only statistically significant difference between the two groups was in RNFL thickness. Memantine group subjects had higher thickness in nasal (P = 0.01), superior (P = 0.006), inferior (P = 0.01) quadrants and average (P = 0.01). However, temporal quadrant thickness was not different between two groups (P = 0.35). CONCLUSION:Memantine was effective in reduction of RNFL thinning, although this structural difference was not associated with improved visual function.
RCT Entities:
BACKGROUND: To determine the effect of memantine on axonal loss and visual function during the course of optic neuritis (ON). METHODS: Sixty ON patients in a single-center, institutional setting were randomly assigned to the memantine or placebo groups. Patients with first attack of acute unilateral optic neuritis, with visual symptoms of 8 days' duration or less were enrolled in this trial. No patient had known multiple sclerosis, and none had taken immunomodulatory agent prior to or at the time of presentation. For all patients, the following characteristics were recorded and compared at initial presentation and 3 months afterward: visual acuity, retinal nerve fiber layer (RNFL) thickness, visual field parameters (mean deviation and pattern standard deviation), visual evoked potential, and contrast sensitivity. RESULTS: Fifty-four patients completed the 3-month follow up. There were no significant differences between the placebo and memantine groups for any of the characteristics at initial presentation. After 3 months, the only statistically significant difference between the two groups was in RNFL thickness. Memantine group subjects had higher thickness in nasal (P = 0.01), superior (P = 0.006), inferior (P = 0.01) quadrants and average (P = 0.01). However, temporal quadrant thickness was not different between two groups (P = 0.35). CONCLUSION:Memantine was effective in reduction of RNFL thinning, although this structural difference was not associated with improved visual function.
Authors: J Vernon Odom; Michael Bach; Colin Barber; Mitchell Brigell; Michael F Marmor; Alma Patrizia Tormene; Graham E Holder Journal: Doc Ophthalmol Date: 2004-03 Impact factor: 2.379
Authors: Markus Bock; Alexander U Brandt; Jan Dörr; Helga Kraft; Nicholetta Weinges-Evers; Gunnar Gaede; Caspar F Pfueller; Katja Herges; Helena Radbruch; Stephanie Ohlraun; Judith Bellmann-Strobl; Jörn Kuchenbecker; Frauke Zipp; Friedemann Paul Journal: Clin Neurol Neurosurg Date: 2010-05-10 Impact factor: 1.876
Authors: Helen V Danesh-Meyer; Stuart C Carroll; Rod Foroozan; Peter J Savino; Jennifer Fan; Yannan Jiang; Stephen Vander Hoorn Journal: Invest Ophthalmol Vis Sci Date: 2006-11 Impact factor: 4.799
Authors: William A Hare; Elizabeth WoldeMussie; Ronald K Lai; Hau Ton; Guadalupe Ruiz; Teresa Chun; Larry Wheeler Journal: Invest Ophthalmol Vis Sci Date: 2004-08 Impact factor: 4.799
Authors: S Anand Trip; Patricio G Schlottmann; Stephen J Jones; Daniel R Altmann; David F Garway-Heath; Alan J Thompson; Gordon T Plant; David H Miller Journal: Ann Neurol Date: 2005-09 Impact factor: 10.422
Authors: Magí Andorrà; Salut Alba-Arbalat; Anna Camos-Carreras; Iñigo Gabilondo; Elena Fraga-Pumar; Ruben Torres-Torres; Irene Pulido-Valdeolivas; Ana I Tercero-Uribe; Ana M Guerrero-Zamora; Santiago Ortiz-Perez; Irati Zubizarreta; Nuria Sola-Valls; Sara Llufriu; Maria Sepulveda; Eugenia Martinez-Hernandez; Thais Armangue; Yolanda Blanco; Pablo Villoslada; Bernardo Sanchez-Dalmau; Albert Saiz; Elena H Martinez-Lapiscina Journal: JAMA Neurol Date: 2020-02-01 Impact factor: 18.302
Authors: Laura J Balcer; Lisanne J Balk; Alexander U Brandt; Peter A Calabresi; Elena H Martinez-Lapiscina; Rachel C Nolan; Friedemann Paul; Axel Petzold; Shiv Saidha Journal: J Neuroophthalmol Date: 2018-12 Impact factor: 3.042
Authors: Jeffrey L Bennett; Molly Nickerson; Fiona Costello; Robert C Sergott; Jonathan C Calkwood; Steven L Galetta; Laura J Balcer; Clyde E Markowitz; Timothy Vartanian; Mark Morrow; Mark L Moster; Andrew W Taylor; Thaddeus W W Pace; Teresa Frohman; Elliot M Frohman Journal: J Neurol Neurosurg Psychiatry Date: 2014-10-29 Impact factor: 10.154